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Summary 
Conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) by TET enzymes 
is critical to DNA methylation reprogramming. Mutation of TET genes in T-cell malignancies 
and loss of TET activity resulting in auto-immune phenotypes in mouse, suggests important 
roles in T-cell biology. Consistent with this, we report early and widespread 5mC/5hmC 
remodeling during human CD4+ T-cell differentiation ex vivo at genes and cell-specific 
enhancers with known T-cell function. We observed similar DNA de-methylation in CD4+ 
memory T-cells in vivo, indicating that early remodeling events persist in differentiated cells. 
Underscoring their important function, 5hmC loci were highly enriched for genetic variants 
associated with T-cell diseases and T-cell-specific chromosomal interactions. Extensive 
functional validation of 22 risk variants revealed novel, potentially pathogenic, mechanisms in 
diabetes and multiple sclerosis. Our results support 5hmC-mediated DNA de-methylation as a 
key component of CD4+ T-cell biology in humans, with important implications for identifying 
disease-associated genetic variants. 
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Highlights 
• 5hmC remodeling is widespread during human CD4+ T-cell differentiation 
• Early 5hmC gains predict loss of DNA methylation in differentiated cells 
• 5hmC remodeling in vitro predicts loss of DNA methylation in vivo  
• 5hmC loci are enriched for functional, T-cell disease associated genetic variants  
 
eTOC 
Nestor, Lentini and colleagues reveal widespread 5hmC-mediated DNA de-methylation during 
in vitro differentiation of human CD4+ T-cells and propose 5hmC profiling as a novel and 
effective approach for the identification of regulatory variants in human disease. 
 
INTRODUCTION 
Differentiation of CD4+ T-cells into effector or regulatory subtypes is critical to adaptive 
immunity. Upon contact with antigens, T-cells differentiate into various T-helper (Th) cell 
subsets, such as Th1, Th2, Th17 or regulatory T (Treg) cells (Yamane and Paul, 2013), which 
mediate or inhibit immune responses. Inappropriate CD4+ T-cell differentiation is associated 
with several autoimmune and inflammatory diseases, including rheumatoid arthritis (RA), 
psoriasis, allergy, asthma, multiple sclerosis (MS) and type 1 diabetes (Gustafsson et al., 2015; 
Licona-Limon et al., 2013; Wahren-Herlenius and Dorner, 2013). The lack of a strong genetic 
component and increasing prevalence of these diseases suggests an epigenetic contribution to 
their pathogenesis, and changes in T-cell DNA methylation patterns have been reported in MS, 
allergy, and RA (Graves et al., 2013; Liu et al., 2013; Nestor et al., 2014a).  
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Appropriate differentiation of Th subsets requires widespread remodeling of the T-cell 
epigenome, including DNA de-methylation of many master regulators of the differentiation 
process, such as Il4, Il5, Il13 (Th2), Ifng (Th1) and FOXP3 (Treg) (Janson et al., 2011; Lee et 
al., 2006). 5-hydroxymethylcytosine (5hmC) was recently discovered to be highly abundant in 
the human genome and generated by hydroxylation of 5-methylcytosine (5mC) by members of 
the Ten-Eleven-Translocation (TET1/2/3) family of enzymes (Tahiliani et al., 2009). 5hmC 
can subsequently be resolved to unmodified cytosine, completing the process of DNA de-
methylation (Figure S1A). Significantly, TET loss-of-function mutations have been identified 
in several hematological malignancies, with the highest frequency in adult CD4+ T-cell 
cancers (Kalender Atak et al., 2012; Lemonnier et al., 2012). Moreover, Tet2 knockout mice 
exhibit impaired differentiation of hematopoietic stem cells and developed autoimmune 
phenotypes (Ichiyama et al., 2015; Ko et al., 2011; Li et al., 2011; Yang et al., 2015). Despite 
the valuable insights into the role of TET-5hmC during differentiation of mammalian CD4+ T-
cells obtained from mouse models (Ichiyama et al., 2015; Ko et al., 2011; Tsagaratou et al., 
2014; Yang et al., 2015), little is known about the importance of DNA de-methylation in human 
CD4+ T-cell differentiation and its contribution to the pathogenesis of complex immune 
diseases.  
We generated genome-wide maps of 5hmC, 5mC and gene expression during early and late 
stages of human CD4+ T-cell differentiation ex vivo. Changes in 5hmC were widespread during 
both activation and differentiation of CD4+ T-cells, occurred at a variety of activating and 
repressive regulatory elements, and coincided with tight regulation of TET gene expression. 
Significantly, all early 5hmC and 5mC remodeling occurred in the complete absence of 
replication, suggesting an ‘active’, enzymatic remodeling mechanism. Using genetic 
overexpression we showed that tight regulation of TET levels was required for appropriate 
expression of key lineage specific transcription factors and cytokines. We confirmed these 
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findings in vivo by transcriptional and epigenetic profiling of human naïve CD4+ T cells (NT), 
central memory (TCM) and effector memory T-cells (TEM). Supporting the disease relevance of 
5hmC-mediated DNA de-methylation, loci gaining 5hmC during early T-cell differentiation 
were highly enriched for variants associated with T-cell related diseases at a diversity of cis- 
and trans- gene regulatory elements. Moreover, these regions were also enriched for T-cell 
specific chromosomal interactions, supporting their importance in T-cell biology. We 
undertook further functional characterization of the effects of over 20 predicted regulatory 
variants on the level of DNA-protein interactions, and reveal novel, potentially pathogenic, 
mechanisms in diabetes and multiple sclerosis. Our results support 5hmC-mediated DNA de-
methylation as a key component of CD4+ T-cell biology in humans, and 5hmC profiling as a 
novel and cost-effective approach for identification of regulatory genetic variants in complex 
immune disease. 
RESULTS 
5hmC remodeling during CD4+ T-cell differentiation occurs in absence of replication and 
is enriched at key regulatory genes 
To dissect the role of DNA de-methylation in human CD4+ T cell function, we took advantage 
of the ability to differentiate pure human naïve T-cells into T helper cell subsets in vitro (Figure 
1A). This powerful approach allowed direct observation of the early 5hmC remodeling events, 
occurring in the absence of DNA replication, that result in the stable lineage-specific 5mC 
profiles observed in differentiated T helper cell subsets. Appropriate differentiation into Th1 
and Th2 lineages was confirmed by gene expression microarray and qRT-PCR of key lineage-
specific genes (Figures S1B-C & Table S1). In vitro polarization of NT cells resulted in a >5-
fold loss (PT-TEST < 0.05) of global 5hmC levels (Figure 1B). A small, but consistent 10-15% 
loss of global 5hmC levels was also observed after only 1 day of in vitro polarization, consistent 
with changes in the 5-hydroxymethylome occurring before the onset of DNA replication 
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(Figures 1B & S1D-E). Next, we combined 5hmC DNA immuno-precipitation with massively 
parallel sequencing (hMeDIP-seq) to generate the first hydroxymethylomes of human CD4+ T-
cells differentiating into Th1 and Th2 effector cells in two replicate experiments. 5hmC profiles 
were generated in naïve cells and both at early (1 day) and late (5 day) time-points during 
polarization, allowing identification of both early replication-independent changes as well as 
later subset-specific changes in 5hmC. We generated 1 billion paired reads in total and for each 
condition 35-60 million paired reads were uniquely mapped to the human genome (hg19) 
(Table S2). 5hmC showed characteristic enrichment in gene bodies and depletion at 
transcription start sites as previously reported in other cell types (Figure 1C) and a clear 
association with actively transcribed genes (Figure 1D) (Nestor et al., 2012; Song et al., 2011). 
Similar to results reported in mouse CD4+ T-cells, the distribution of 5hmC enrichment was 
significantly overrepresented in genic regions in all T-cell subsets (Figure 1E & Table S2) 
(Ichiyama et al., 2015; Tsagaratou et al., 2014).  
To understand the biological relevance of these changes, we mapped the 1,000 largest 
gains and losses of 5hmC to their nearest gene and subjected these to gene ontology (GO) 
enrichment analysis. Strikingly, whereas regions losing 5hmC were not enriched in any 
biological processes, regions gaining 5hmC at day 1 in either Th1 or Th2 cells were highly 
significantly (PADJUSTED < 1 x 10-8) enriched for genes associated with T-cell activation (Figure 
1F and data not shown), including the signature genes IFNG, TBX21, FOXP3, ZAP70, IL2RA, 
IL7R, IRF4, CD5, AIM2, CCR2, CCR5, IL1R2, IL26 and IL32R (Figure 1G and data not 
shown). Globally, large-scale remodeling of 5hmC had occurred by day 1, with over 10,000 
and 5,000 regions significantly gaining or losing 5hmC, respectively (Figure S1F and Table 
S2). The scale of change was far greater in regions gaining 5hmC (Figure S1G).  
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Taken together, these results reveal genome-wide, replication-independent re-
programming of 5hmC during CD4+ T-cell differentiation at genes key to appropriate T-cell 
activation and differentiation.  
 
Lineage specification of human CD4+ T-cells is preceded by 5hmC-mediated DNA de-
methylation of gene regulatory elements  
To relate 5hmC remodeling during differentiation to changes in DNA methylation (5mC), we 
subjected the same in vitro differentiated human Th1 and Th2 cells to DNA methylation 
profiling using Infinium 450K methylation arrays. Although not genome-wide, these arrays 
provide quantitative, base-resolution methylation measurements at ~450,000 CpG sites 
throughout the genome, allowing accurate detection of even small (> 3%) changes in absolute 
methylation levels. We observed a clear bias towards loss of 5mC in both Th1 and Th2 
differentiated cells with more pronounced changes occurring by day 5 (Figure 2A). However, 
some changes in DNA methylation were also observed at day one (123 CpGs >10% loss, P < 
0.05), in complete absence of replication (Figures S2A & Table S3) suggesting that such 
changes are active, and not secondary to DNA replication. Importantly, regions gaining 5hmC 
at day one of differentiation in both Th1 and Th2 cells were highly significantly enriched for 
CpGs losing 5mC at day 5 (P < 0.0001, Fisher exact test) (Figures 2B & S2B), suggesting that 
DNA de-methylation at these loci occurs primarily via a 5hmC-mediated process. Indeed, loci 
showing the greatest loss of 5mC during Th1 and Th2 differentiation were also those showing 
the greatest gains in 5hmC after only 1 day of polarization (Figure 2C). Finally, genes showing 
loss of DNA methylation (> 30% loss of 5mC) in their promoters during differentiation were 
enriched for functional terms related to the immune response (Figure S2C), further indicating 
that DNA de-methylation occurs in a targeted manner. Taken together, these findings suggest 
a model whereby loci to be de-methylated in differentiated T-cell subtypes first undergo 
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enzymatic hydroxylation of 5mC to 5hmC followed by both replication-independent excision 
and replication-dependent dilution of 5hmC during successive rounds of DNA replication.  
As the majority (> 95%) of loci undergoing 5hmC remodeling during early CD4+ T-
cell differentiation occurred outside annotated gene promoters, we hypothesized that these loci 
might represent gene regulatory elements. Indeed the TET enzymes interact with numerous 
chromatin modifiers (HDAC1, HDAC2, EZH2, SIN3A) and co-repressor complexes (NuRD) 
which may serve to target TET methylcytosine dioxygenase activity to regulatory elements 
within the genome (Delatte et al., 2014) and elevated 5hmC levels have been observed at active 
enhancers in several systems (Lu et al., 2014; Tsagaratou et al., 2014). Using published 
chromatin-immunoprecipitation (ChIP)-sequencing data, we analyzed the association between 
5mC/5hmC remodeling in CD4+ T-cells and the enhancer-associated histone modifications, 
H3K4me1 and H3K27ac (Hawkins et al., 2013) (Figure 2D). Indeed, Th1- and Th2-specific 
active enhancer elements marked by H3K27ac (Hawkins et al., 2013) were highly enriched for 
regions showing 5mC loss during differentiation (~15-fold, p < 0.001) (Figures 2E-G).   
 
Ectopic expression of TET1 results in dysregulation of key cytokine and chemokine genes 
during differentiation 
Expression profiling by qPCR showed that TET1, in contrast to TET2 and TET3, was highly 
expressed in T-cells, as well as thymus compared to other human tissues and immune cells 
(Figure 3A & Figure S3A). Moreover, whereas the absolute levels of TET1 were lower than 
those of TET2 and TET3 during T-cell differentiation, TET1 alone underwent, rapid and stable 
down-regulation during early T-cell activation (>10-fold reduction; P < 0.01, t-test) (Figures 
3B-3C & Figure S3B). Indeed, TET1 silencing was observed as early as 6 hours after initiation 
of differentiation (Figure S3B). Unlike Tet2 and Tet3, Tet1 has been shown to bind to 
Polycomb target gene promoters and associate with chromatin repressors, thereby having a role 
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in direct transcriptional repression unrelated to its enzymatic activity (Williams et al., 2011; 
Wu et al., 2011). Thus, we sought to dissect the functional role of TET1 during early T-cell 
differentiation by ectopic expression of full-length human TET1 (TET1fl) (Tahiliani et al., 
2009), the catalytic domain of TET1 (TET1cd) or a mutated catalytic domain of TET1 
(TET1mut) lacking enzymatic activity (Guo et al., 2011) (Figures 3D and S3C-D). Notably, 
overexpression of TET1fl led to significant dysregulation of chemokine and cytokine gene 
mRNA levels (log2FC >0.5), including several key regulators of Th1/Th2 differentiation, 
including IFNG, IL12RB2, HAVCR2, GATA3 and IL5. (Figures 3E and S3E). Far fewer 
changes in gene expression were observed with TET1cd (Figures 3F and S3F, Table S4), the 
majority of which were associated with calcium ion channel activity (Figure S3F). These 
findings suggests that TET1 might act as a direct transcriptional repressor during T-cell 
differentiation. However, as the transcriptional programs of each T helper subset generally 
inhibit those of the other lineages future studies are warranted to fully elucidate the functional 
role of TET1. Nevertheless, the results clearly support an important role for TET1 in the 
regulation of key genes during lineage-specification of T-helper cell subsets. 
 
5hmC remodeling during early differentiation of human CD4+ T-cells predicts loss of 
5mC in CD4+ memory T-cells in vivo. 
We and other have previously shown that adaptation of primary mammalian cells to culture 
can affect the genomic distribution of 5hmC (Nestor et al., 2012; Nestor et al., 2015). Thus, 
having determined the DNA methylation dynamics of human T-cell differentiation in vitro, we 
sought to establish if similar changes occurred in vivo. After activation and differentiation of 
naïve T-cells (NT), a small proportion of cells remain as long-lived memory cell populations, 
which can be sub-divided into central memory (TCM) and effector memory (TEM) subsets based 
on their function and homing capacity (Sallusto et al., 2004). We isolated primary human NT 
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(CD4+CD45RO-CCR7+), TCM (CD4+CD45RO+CCR7+) and TEM (CD4+CD45RO+CCR7-) 
cells by FACS (purity >95%) for analysis (Figure S4A). Consistent with our findings in 
polarized T-cells, in vivo memory subsets exhibited decreased (P < 0.05, t-test) levels of TET1 
and TET3 (Figure 4A) as well as lower global 5hmC content (Figure 4B), verifying that TET 
inactivation events observed during polarization also occur in vivo. Next, we generated gene 
expression and genome-wide DNA methylation profiles for NT, TCM and TEM cells. Gene 
expression of TCM and TEM cells showed distinct profiles, with TEM cells expressing high levels 
of effector molecules such as IL4, IFNG and CSF2, while TCM cells showed an intermediate 
profile, both in expression levels and number of genes up- or downregulated (Figure 4C, S4B-
C & Table S5), consistent with a linear differentiation program of NT  TCM  TEM. 
Interestingly, DNA methylation profiles could clearly separate NT, TCM and TEM cells 
indicating that each subset is epigenetically distinct (Figure 4D & S4D). Furthermore, TEM 
cells showed extensive genome-wide de-methylation, exceeding that of TCM (Figure 4E), 
consistent with the notion that TEM cells are more terminally differentiated. As expected, DNA 
methylation changes in gene promoters was correlated with gene expression (rho = -0.43, p = 
5.9e-08) (Figure 4F). Having characterized methylome- and transcriptome dynamics in 
memory T-cells, we sought to relate these changes to early hydroxymethylome reprogramming 
during T-cell polarization. Consistent with our findings in polarized T-cells, regions gaining 
5hmC after one day of polarization exhibited extensive de-methylation in memory cells (P = 
6.20e-78, Fisher’s exact test) (Figure 4G-I). As 5hmC and 5mC cannot be distinguished by 
conventional bisulfite conversion (Nestor et al., 2014b), we performed 5hmC/5mC-specific 
qPCR for selected loci undergoing 5mC changes in NT, TCM and TEM cells (Figure S4E-F, 
Table S6).  
 Thus, early methylome-reprogramming events initiated by 5hmC are maintained long-
term in memory T-cells in vivo.  
Nestor et al. DNA de-methylation during T-cell differentiation 
11 
 
 
5hmC remodeling marks regulatory regions enriched for disease-associated genetic 
variants 
Consistent with previous reports in other cell types (Wu and Zhang, 2014), 5hmC in CD4+ T-
cells marked several different types of gene regulatory elements (such as enhancers, promoters 
and gene bodies). Using a Hidden Markov model together with published genome-wide data 
sets for several epigenetic marks in primary human NT cells (Bernstein et al., 2010; Song and 
Chen, 2015) (Table S7) we observed that 5hmC occupied a unique position in the genome, 
associating with both repressive and activating states, supporting the property of 5hmC as a 
general marker of gene regulatory activity (Figure 5A). Since the majority of disease-
associated variants are found in non-coding regions, we compared the frequency of all disease-
associated variants reported at the time of analysis (NleadVariant = 73,196; P < 1x10-5, GWASdb2) 
(Li et al., 2012) and those in high LD (NVARIANT = 600,320, r2 > 0.8, 1000 Genomes Project, 
phase 3)  in regions gaining or losing 5hmC at day 1 of in vitro polarization, resulting in a total 
of 1,560 variants (Table S8). Regions gaining 5hmC (hereafter referred to as “5hmC regions”) 
were significantly enriched (P < 0.01) for disease associated variants in 19 diseases, where six 
out of the top ten diseases were autoimmune whereas regions losing 5hmC showed no 
significant enrichment for CD4+ T-cell diseases (Figure 5B). Strikingly, regions gaining 5hmC 
were twice as likely (OR 2.6, p < 0.0001; Fisher’s exact test) to overlap a disease-associated 
variant than cell type-specific enhancers (Figure 5C) (Hawkins et al., 2013).  
5hmC has previously been associated with transcription factor binding sites (TFBS) 
(Yu et al., 2012) suggesting that variants in 5hmC regions may modulate gene expression by 
disrupting TF binding. We tested all 1,560 5hmC variants using phylogenetic module 
complexity analysis (PMCA), leveraging the conservation of co-occurring transcription factor 
binding site (TFBS) patterns within gene regulatory modules, as previously described by us 
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(Claussnitzer et al., 2014). Interestingly, for the variants in 5hmC regions we found 49.4% 
predicted to be regulatory compared to our previous findings of 33.3% in a random set of 
variants (Claussnitzer et al., 2014) (Table S8). To experimentally evaluate the effects of 
identified non-coding variants on regulatory protein binding we performed electrophoretic 
mobility-shift assays (EMSAs) using nuclear protein extracts from both transformed and 
primary, trait-related human CD4+ T-cells, using probes for the risk and non-risk alleles of 22 
variants (44 alleles) (Table S9). First, we tested variants associated with Crohn’s disease and 
multiple sclerosis, as these diseases showed the highest enrichment for variants in 5hmC 
regions (Figure 5B & Table S8). We also tested variants associated with non-enriched T-cell 
associated diseases (such as allergy) and other non T-cell associated traits (obesity, metabolite 
levels) with high TFBS module conservation (Figure 5B & Table S8). We found an allele-
specific shift in 16 out of 22 tested variants when using protein extracts from the Jurkat T-cell 
line (Figure 5D & Figure S5A), supporting that 5hmC can aid in the identification of 
regulatory variants, potentially contributing to disease pathophysiology. Importantly, variant-
induced alterations on regulator binding could be replicated by using nuclear protein from 
primary human CD4+ T-cells isolated from healthy individuals (Figure 5E). 
As none of the risk variants affecting regulator binding were located within gene 
promoters or gene coding regions, we assessed how risk variants might modulate gene 
expression via physical interaction with distal gene regulatory elements. Using chromatin 
interaction data (capture Hi-C; cHi-C) for a human CD4+ T-cell line (Martin et al., 2015) we 
found that disease-associated variants located in 5hmC regions were significantly enriched 
(PBOOTSTRAP < 1x10-4) for long-range chromatin interactions compared to all disease-associated 
variants (Figure 5F). Interestingly, enrichment of chromatin interactions for disease-associated 
variants in 5hmC regions was greater than that observed for T-cell specific enhancers (Hawkins 
et al., 2013) even though, not surprisingly, enhancer regions alone had a significantly higher 
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number of chromatin interactions compared to 5hmC regions (Figure 5F and data not 
shown). These findings strongly support the power of 5hmC as a precise and efficient marker 
to identify regulatory disease-associated variants. 
To further validate our approach we examined interactions at the CLEC16A locus, 
which is associated with several autoimmune diseases (Wellcome Trust Case Control, 2007) 
(Figure 5G). Out of 30 variants in high LD (r2>0.8), five were located in 5hmC regions, two 
of which were significantly enriched for TFBS module conservation (Table S8). For these two 
variants, we observed differential protein binding for rs7203150 in both Jurkat and primary 
human CD4+ cells (Figure 5D and E, P = 5.9 x 10-7 / 1.8 x 10-3, respectively, Student’s t test), 
whereas no allele specific binding was observed for rs7198004 (Table S8, Figure S5A). The 
variant rs7203150 is located in intron 19 of the CLEC16A gene, containing many variants 
associated with multiple autoimmune diseases and has been shown to physically interact with 
and regulate the expression of a neighboring gene, DEXI (Davison et al., 2012). Capture Hi-C 
data confirmed the highly significant interaction of the rs7203150 region with the DEXI 
promoter (FDR<5%), as expected, but also revealed a novel interaction with a downstream 
gene, RMI2 (Figure 5G). In fact, cHi-C data suggest interactions for numerous genes at the 
CLEC16A locus, SOCS1,a negative regulator of cytokine signaling (Diehl et al., 2000), DEXI, 
a gene of unknown function but proposed as autoimmune candidate gene (Leikfoss et al., 
2013), RMI2, a topoisomerase critical for T-cell differentiation and a primary 
immunodeficiency syndrome candidate gene (Monnich et al., 2010), to CLEC16A, recently 
shown to affect T-cell selection, mediate T1D and modify CD4 single positive thymocyte 
reactivity (Schuster et al., 2015) (Figure 5G). Finally, in our T-cell data we find supportive co-
expression of CLEC16A with CIITA, SOCS1, DEXI and RMI2 (Figure 5G, right panel).  
Thus, 5hmC remodeling marks cell-type specific, gene regulatory regions, which may 
contribute to pathogenic mechanisms in CD4+ T-cell associated diseases. 
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DISCUSSION  
Previous studies of 5hmC during T-cell differentiation have reported global loss of 5hmC in 
differentiated T helper subsets in mouse (Ichiyama et al., 2015; Tsagaratou et al., 2014; Yang 
et al., 2015). We confirm these findings, but using a time-series profiling approach, we also 
report widespread 5hmC remodeling during early differentiation, including >10,000 locus-
specific gains of 5hmC enriched at genes associated with T-cell function. Here, we report that 
5hmC-mediated DNA de-methylation is a key feature of human CD4+ T-cell differentiation 
and that tight regulation of TET gene expression is critical for appropriate differentiation of T-
helper subsets. These DNA de-methylation events were also observed in memory T-cells in 
vivo and were enriched for variants associated with CD4+ T-cell diseases including multiple 
sclerosis, psoriasis and Crohn’s disease. Several disease-associated variants affected DNA-
protein interactions in primary human CD4+ T-cells and reveal novel, potentially pathogenic 
mechanisms in several autoimmune diseases. To our knowledge this is the first time de-
methylation events have been used to trace disease-associated variants in a trait-related cell 
type. As 5hmC profiling can be performed on small amounts (> 25 ng) of archived, fragmented 
genomic DNA it is ideal for identifying and stratifying potential regulatory variants in rare 
primary cell types (Taiwo et al., 2012). This is in contrast to chromatin-based enhancer-
profiling strategies which typically requires profiling of multiple epigenetic marks in large 
amounts of fresh material (Hawkins et al., 2013). 
Studies in mouse have provided valuable insights into the role of DNA methylation 
during differentiation of mammalian CD4+ T-cells, but less is known about the importance of 
DNA de-methylation in human CD4+ T-cell differentiation and its contribution to the 
pathogenesis of complex immune diseases (Ichiyama et al., 2015; Ko et al., 2011; Tsagaratou 
et al., 2014; Yang et al., 2015). Our profiling of the methylome (5mC), hydroxymethylome 
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(5hmC) and transcriptome of matched human CD4+ T-cells during in vitro differentiation of 
naïve T-cells (NTs) into T-helper type 1 (Th1) and T-helper type 2 (Th2) cells revealed 
widespread remodeling of 5hmC during early T-cell activation, and that early gains in 5hmC 
predicted subsequent loss of 5mC in differentiated Th1 and Th2 cells. Significantly, 5hmC 
remodeling was enriched in the regulatory regions of genes with known T-cell function 
including master regulators of lineage specification, such as IFNG, TBX21 and FOXP3.  
Consistent with an important role for 5hmC mediated DNA de-methylation in T-cell 
differentiation, we found that (i) the TET genes are most highly expressed in T-cell related 
tissues (CD4+ T-cells, CD8+ T-cells, thymus) in humans (ii), CD4+ T-cell activation results in 
dramatic (10-fold) and rapid (6 hours) down-regulation of TET1 expression, and (iii) 
dysregulation of TET1 expression disrupts CD4+ T-cell differentiation. These observations are 
consistent with a growing number of studies in Tet knock-out mice which have revealed a 
pivotal role of TET enzymatic activity in T-cell biology (Ichiyama et al., 2015; Ko et al., 2010; 
Tsagaratou et al., 2014; Yang et al., 2015).  
In addition to direct differentiation into effector subtypes, a proportion of activated NT 
cells become long-lived and retain ‘memory’ of the initial activating signal (Sallusto et al., 
1999). Methylome profiling of NT, TCM and TEM cells ex vivo, revealed that the DNA 
methylation changes observed early during differentiation persist in memory T-cells. First, this 
important observation supports the validity of in vitro CD4+ T-cell differentiation as a powerful 
model system in which to study the epigenetics of human CD4+ T-cells. Second, these data 
suggest that any dysregulation of the DNA de-methylation pathway will not only affect 
immediate response to antigen (differentiation), but also appropriate formation of T-cell 
memory. 
The availability of global profiles for several activating and repressive epigenetic marks 
allowed us to study the epigenetic neighborhood occupied by 5hmC in human CD4+ T-cells. 
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We used a recently described Hidden Markov model based approach to identify the distinct 
chromatin states present in human naïve CD4+ T-cells (Song and Chen, 2015). Interestingly, 
instead of simply following the patterning of 5-methylcytosine, from which it is derived, 5hmC 
was present in chromatin states composed of activating, repressive and poised histone 
modifications (Figure 5A). 5hmC’s presence across so many chromatin states may reflect its 
property as an intermediate during conversion of transcriptionally repressive 5-methylcytosine 
to transcriptionally permissive unmodified cytosine (Hon et al., 2014). Alternatively, 5hmC’s 
association with such a diverse range of histone marks may reflect the growing realization of 
the TET enzymes as multi-faceted proteins, connecting different layers of epigenetic and 
transcription control to maintain cell state (Laird et al., 2013). Indeed, the TET enzymes have 
been reported to directly interact with transcriptional activators including PU.1, EBF1 and 
p300, while also interacting with proteins associated with transcriptional repression, including 
EZH2, SIN3A, HDACs, NuRD and MeCP2 (Cartron et al., 2013; Delatte et al., 2014). 
Regardless of the underlying mechanism, 5hmC’s position as a general but sensitive indicator 
of chromatin state make it a powerful tool in the identification of cell-type specific regulatory 
elements. Indeed, regions gaining 5hmC during early activation (day 1) were highly enriched 
for variants associated with several autoimmune diseases including Crohn’s disease, multiple 
sclerosis, celiac disease, myasthenia gravis and psoriasis. The effect of these potentially 
regulatory variants on DNA-protein binding was directly tested in primary human CD4+ T-
cells and provides multiple molecular pathways for further investigation. By combining these 
results with chromatin interaction (capture Hi-C) data from a human T-cell line we found that 
5hmC variants are enriched for connections between distal regulatory elements and identify 
several interactions, which if disrupted by risk variants, may have pathogenic consequences in 
autoimmune disease. Notably, dynamic 5hmC regions were more enriched for regulatory 
interactions than cell-type specific enhancers identified by profiling of multiple histone marks 
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(Hawkins et al., 2013). Combined with the ability to perform 5hmC-profiling on small amounts 
of archived DNA, this surprising and provocative finding suggests that 5hmC alone may be a 
powerful and cost-effective approach for prioritization of regulatory variants in humans. 
In conclusion, 5hmC-mediated DNA de-methylation plays key roles in the 
differentiation of human CD4+ T-cells, marking regions relevant for the pathogenesis of several 
autoimmune diseases and represents a novel, inexpensive and accessible approach for 
identifying causal disease variants in autoimmune disease.  
 
EXPERIMENTAL PROCEDURES 
Ethics Statement 
This study was approved by the ethics board of Linkoping University and all participants 
provided written consent for participation. 
 
Cell Isolation and stimulation 
Peripheral blood mononuclear cells (PBMCs) were enriched from healthy donor buffy coats 
using Lymphoprep (Axis-shield). Human total CD4+ T-cells or Naïve CD4+ T-cells were then 
isolated through magnetic sorting (Miltenyi Biotec). Naïve T-cells were cultured with plate 
bound anti-CD3 (500ng/µL) and soluble anti-CD28 (500ng/µL) in the presence of IL-12 
(5ng/mL), IL-2 (10ng/mL) and anti-IL4 (5µg/mL) for Th1- or IL-4 (10ng/mL), IL-2 
(10ng/mL), anti-IFNG (5µg/mL) and anti-IL12 (5µg/mL) for Th2 conditions. Cells were grown 
for up to five days in RPMI-1640 medium (Life technologies) supplemented with 2mM L-
glutamine (PAA laboratories), 10% heat-inactivated FCS (PAA laboratories) and 50µg/mL 
gentamicin (Sigma-Aldrich). Cells were re-stimulated with respective condition (see above) 
after three days in culture.  
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DNA and RNA extraction 
Total RNA and genomic DNA was extracted using AllPrep DNA/RNA mini kit (Qiagen). 
DNA and RNA integrity was determined using a 2100 Bioanalyzer (Agilent). 
 
hMeDIP-Seq and data analysis 
DNA (1.5µg) was fragmented by sonication using a Bioruptor (6 x 15min 30s on/off, 
Diagenode) then subjected to end-repair, dA-tailing, and adaptor-ligation using the NEBNext 
DNA Library Prep Master Mix Set for Illumina (New England Biolabs). Samples were 
hydroxymethylated DNA immuno-precipitated (hMeDIP) as previously described (Nestor et 
al., 2012). Briefly, DNA was denatured and incubated with 1μg antibody against 5hmC 
(ActiveMotif; #39769) overnight at 4°C. IP and input DNA was prepared using magnetic beads 
(Dynabeads Protein G; Invitrogen) and amplified using NEBNext Multiplex Oligos for 
Illumina (New England Biolabs). Samples were separated by electrophoresis on a 2% low 
melting point agarose gel and fragments between 100 – 400 bp were selected. DNA was 
purified using the QIAquick Gel Extraction Kit (QIAGEN) and sequenced on an Illumina 
HiSeq 2000 platform. Reads were mapped to the human genome (hg19) using bowtie with the 
following parameters (bowtie –v 1 – best -S). Peak calling was performed using MACS with 
input samples as control.   
 
Immuno dot-blotting 
DNA was denatured and applied to a positively charged nylon membrane under vacuum using 
a Dot Blot Hybridisation Manifold (Harvard Apparatus Limited, UK). The membrane was 
washed twice in 2X SSC buffer, air-dried and UV-crosslinked. Membranes were incubated 
with an antibody against 5hmC (1:3000, Active Motif) for 1h at 4°C then washed in TBS-
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Tween (0.05%) and incubated with a HRP conjugated goat-anti-rabbit antibody (1:10000, Bio-
Rad). Following treatment with enhanced chemiluminescence (ECL) substrate, membranes 
were scanned on a ChemiDoc MP imaging system (Bio-Rad). To control for loading, 
membranes were stained with methylene blue. Spot intensities were quantified using ImageJ 
(NIH). 
 
Gene expression microarrays and analysis 
For gene expression microarrays, RNA was labeled and amplified using the Low Input 
Quick Amp Labeling kit (Agilent Technologies), then hybridized onto SurePrint G3 Human 
Gene Expression 8x60K v2 microarrays (Agilent Technologies) and scanned using a Surescan 
High Resolution DNA Microarray Scanner (Agilent Technologies). Raw intensities were 
exported with Agilent’s Feature Extraction Software. All subsequent analyses were performed 
using the LIMMA package in the R statistical programming language. Briefly, data was 
background corrected and quantile normalized then control probes, probes not expressed 
(background +10%) in all conditions and non-annotated probes were removed.  
 
Statistical analysis 
P-values < 0.05 were considered significant and when stated, p-values were adjusted using 
Benjamini-Hochberg correction.  
 
Data access 
 All raw and processed microarray and next-generation sequencing data will be made 
publically available in the ArrayExpress database. 
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FIGURE LEGENDS 
Figure 1. Dynamic remodeling of 5-hydroxymethylcytosine (5hmC) during in vitro 
polarization of human CD4+ T-cells. 
(A) Schematic figure of experimental design for T-cell polarization. 
(B) Global 5hmC content measured by immuno-dot blot using a 5hmC antibody. Naïve T-cells 
(NT) were cultured under Th1 or Th2 polarizing conditions for up to 5 days. Brain is shown as 
a tissue with high 5hmC content. Data shown as mean ±SD, representative of 5 biological 
replicates. *p<0.05 Student’s t test. 
(C) Normalized 5hmC density profiles across gene body ± 4 kb flanking regions. 
(D) Normalized 5hmC density profiles across gene body ± 2 kb flanking regions in NT cells 
binned into three equal sized groups based on gene expression levels. 
(E) Genomic distribution of 5hmC peaks during T-cell differentiation in vitro. ***p<0.001 
Fisher’s Exact test.  
(F) Gene ontology (GO) enrichment of 5hmC peaks in T-cells differentiated in vitro for 1 day. 
Nestor et al. DNA de-methylation during T-cell differentiation 
24 
 
(G) Coverage plots of 5hmC levels at IFNG, IL4, IL5, AIM2 and IL23R loci showing subset 
specific changes. 
See also Figure S1 
 
 
Figure 2. DNA de-methylation occurs via 5-hydroxymethylcytosine (5hmC) during in 
vitro differentiation of human CD4+ T-cells. 
(A) Volcano plot showing changes in DNA methylation (5mC) during in vitro polarization of 
CD4+ T-cells relative to Naïve T-cells (NT). Vertical lines indicates a change of 20%. 5mC 
measured by 450K methylation array. 
(B) 5hmC regions show major loss of 5mC during T-cell polarization. Background represents 
a randomly sampled group with the same size of probes in 5hmC peaks. Fisher’s exact test was 
used to calculate significance (rightmost).  
(C) Line plot (top) showing regions getting hypomethylated typically gain 5hmC at day 1 of T 
cell polarization. Box plot (bottom) showing genes associated with regions becoming 
hypermethylated decrease in expression levels. ***p<0.001 one-way ANOVA Tukey’s test. 
(D) Coverage plot showing active enhancers (H3K4me1, H3K27ac) gaining 5hmC and losing 
5mC during T-cell polarization. Representative loci of AIM2 and CCL5 shown. 
(E) Bar chart of 5mC changes in T-cell specific enhancer regions (H3K4me1, H3K27ac) show 
higher degree of remodeling in these regions compared to genome-wide. 5mC was measured 
by 450K methylation array. 
(F,G) Distribution of 5mC changes at T-cell specific enhancers (H3K4me1, H3K27ac) show 
an early loss of 5mC in these regions.  
See also Figure S2 
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Figure 3. Tight regulation of TET gene expression is required for appropriate T-cell 
differentiation 
(A) Barplot of TET1 gene expression in healthy human primary tissues (pool of at least 5 
individuals) and primary immune cell subsets analyzed by qPCR. NT: Naïve T-cell. 
(B, C) Barplots of TET gene expression measured by qPCR in Naïve T-cells (NT) cultured 
under Th1 or Th2 polarizing conditions. Expression levels shown relative to GUSB. Data 
shown as mean ±SD, representative of 3 biological replicates. *p<0.05, **p<0.01 Student’s t 
test. 
 (D) Schematic figure of plasmids containing full length TET1 (TET1fl), catalytic domain of 
TET1 (TET1cd) and mutated catalytic domain of TET1 (TET1mut). 
(E, F) Barplots of gene expression for selected genes in NT cells transfected with TET1 
plasmids then cultured under Th1 polarizing conditions for 24h. Lines indicate a log2 fold 
change of 0.5. Gene expression measured by microarray. 
See also Figure S3 
 
Figure 4. Early DNA methylation remodeling persists in CD4+ memory T-cells in vivo. 
(A) Barplot of TET gene expression in primary CD4+Naïve T-cells (NT), central memory 
(TCM) and effector memory (TEM) cells. Gene expression of TET1/2/3 was measured by 
qPCR.  
(B) Barplot of global 5hmC content measured by immuno-dot blot using a 5hmC antibody in 
primary NT, TCM and TEM cells.  
(C) Heatmap of gene expression in primary NT, TCM and TEM cells showing subset specific 
gene signatures. Gene expression measured by microarray. 
(D) Unsupervised hierarchical clustering of DNA methylation (5mC) in NT, TCM and TEM 
cells measured by 450K methylation array. Significance calculated by bootstrap resampling. 
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(E) Volcano plot of 5mC changes in memory subsets showing a predominant loss in both TCM 
and TEM cells. Vertical lines indicate a change of 30%. 
(F) Correlation between 5mC and gene expression in TEM cells calculated using Spearman’s 
rank correlation coefficient. 5mC measured by 450k array and gene expression measured by 
microarray. 
(G) 5hmC regions show major loss of 5mC in TEM cells. Background represents a randomly 
sampled group with the same size of probes in 5hmC peaks. Significance calculated using 
Fisher’s exact test (rightmost). 
(H) Venn diagram of sites losing 5mC in TEM cells and after 5 days of polarization towards 
Th1 and Th2. Sites losing 5mC defined as a loss of 20% or 30% 5mC vs. NT for polarization 
and TEM, respectively, and p<0.05. P-value for overlaps calculated using Fisher exact test. 
(I) Coverage plot of 5mC in NT,TCM and TEM cells showing loss at representative loci 
marked by 5hmC during in vitro polarization of T-cells. ***p<0.001 Student’s t test. 
(A,B) Data shown as mean ±SD of at least 3 biological replicates. *p<0.05, 
**p<0.01,  ***p<0.001, Student’s t test. 
 
Figure 5. 5hmC regions are highly enriched for disease-associated variants. 
(A) ChromHMM heatmap of enrichment and colocalization of 5hmC with other epigenetic 
marks in Naïve CD4+T-cells.  
(B) Enrichment of disease-associated variants in peaks gaining- (left) and losing 5hmc (right) 
after 1 day of CD4+T-cell polarization. 
(C) Venn diagram of disease-associated variant localization in 5hmC 1 day gain peaks and 
CD4+T-cell enhancers.  
(D,E) EMSA analysis of protein-DNA binding showing changes in binding upon introduction 
of disease-associated variantSNPs in 5hmC regions using nuclear protein extracts from Jurkat 
T-cell line (D) and primary CD4+T-cells (E). Dashed boxes indicate shifts in binding, arrows 
indicate shifts not observed in cell line.  
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(F) Barplot of capture Hi-C (cHi-C) interactions overlapping variants in identified 5hmC 
regions or T-cell enhancers. Region sizes were normalized to avoid size bias and P-values 
calculated using bootstrap resampling n=10,000. 
(G) Genomic plot of variant rs7203150 located in identified 5hmC region showing interactions 
with nearby gene promoters (left). Heatmap of co-expression during T-cell polarization 
showing high degree of co-expression between genes interacting with variant rs7203150 
(right). cHi-C: capture Hi-C. 
See also Figure S5 
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